+44 (0)1865 618230
Fax +44 (0)1865 618220
Professor of Translational Neuroscience
I am a clinician scientist working mostly on Alzheimer’s Disease but also on other neurodgeneration disorders such as Parkinson’s disease. Ultimately my group’s research is focussed on trying to find treatments, especially in the early preclinical or prodromal phase of disease. A successful therapy in this phase would delay or prevent symptoms; sometimes referred to as secondary prevention.
With this end in mind my team’s research includes understanding mechanisms and developing novel therapeutic targets, on finding biomarkers to facilitate clinical trials in the early phases of disease and the use of informatics to derive useful information from large datasets, both molecular and clinical.
The lab group’s work is described here http://www.psych.ox.ac.uk/research/dementia-research-group and the ARUK Oxford Drug Development Institute led by Lovestone and Bountra is here http://oxford-ddi.alzheimersresearchuk.org/
You can find me on Twitter here
Identification of a possible proteomic Biomarker in Parkinson’s Disease: Discovery and Replication in Blood, brain and CSF
WINCHESTER L. and NEVADO-HOLGADO A., (2022), Brain Communications
Ng B. et al, (2022), Brain Commun, 4
Park YH. et al, (2020), Neurobiol Aging, 88, 24 - 32
Tau pathology in early Alzheimer’s disease is linked to selective disruptions in neurophysiological network dynamics
Kocagoncu E. et al, (2020), Neurobiology of Aging
Westwood S. et al, (2020), J Alzheimers Dis, 74, 213 - 225